LifeSci Capital initiated coverage of Molecular Partners (MOLN) with an Outperform rating and $12 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOLN:
- Molecular Partners AG: Strong Financials and Promising Pipeline Justify Buy Rating
- Molecular Partners AG: Strategic Advances and Financial Overview
- Molecular Partners and Orano Med Expand Cancer Therapy Collaboration
- Molecular Partners Expands Radio-DARPin Pipeline and Advances Clinical Trials at Healthcare Conference